Advanced searches left 3/3
Search only database of 8 mil and more summaries

World Pharmaceutical Co Ltd

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

With demand for treatments ever increasing, pharmaceutical companies around world are committed to driving critical innovation to deliver therapies for patients with unmet medical needs. In 2019, global pharmaceutical industry will continue to grow at a rapid pace, making an estimate of 1. 3 trillion. As expect, this was largely driven by new product launches such as AbbVieas Skyrizi and Novartisa Zolgensma. Slightly down from 2018, US FDA approved 48 new drugs and biologics in 2019, which still come in as third biggestaapprovalaclass in the past 25 years. Fda approved an impressive number of generics with a huge 1, 171 approvals, breaking its previous record of 971 in 2018. With tough losses of patents for pharma companies, new product launches are becoming increasingly important. The Covid-19 pandemic, which was first discovered at the end of 2019, has had unprecedented impact on world. Looking forward, communities across the globe are relying on pharmaceutical industry to create solutions, and many of companies in the top 10 are involved in the race to produce treatment or prevention measures for Covid-19 disease. In 2020, we expect the effect of Covid-19 pandemic to become clearer, although since access to healthcare providers has been restrict, majority of pharma companies in top 10 have been negatively impact. Ranking in at number 10 is American multinational, Amgen. With its abiology-first approacha, Amgen produces Innovative Medicines and delivers them to 100 countries and regions worldwide. In 2019, Amgenas revenue fell by 1 %, largely caused by a decrease in revenue for Neulasta and Sinsipar / Mimpara which were both impacted by pressure from increased competition. In earnings call, Amgenas Chairman and CEO, Robert. Bradway, confirm company is entering a new phase of new product revenue growth. Staple to top 10 pharmaceutical companies is French multinational pharmaceutical giant, Sanofi. Sanofi provides healthcare solutions to 170 countries worldwide and has three core focuses: speciality care, vaccines and general medicines. In 2019, Sanofias pharmaceutical segment will grow by 4 % on a year-on-year basis, with stellar performance from recently launched Eczema treatment Dupixent, which is set for further growth as Sanofi plans to extend its reach to another 89 countries. Looking to future, Sanofias R & D pipeline is in strong position to produce long-term growth. At the end of July 2020, R & D programme had 83 projects, including 33 new molecular entities in clinical development. Found 133 years ago, Bristol-Myers Squibb is a leading global pharmaceutical company that specialises in medicinal advancements in four key areas: Oncology, haematology, immunology and cardiovascular disease. The Companies continue to produce strong growth in 2019, with revenues increasing by 15 % year-on-year. In 2019, Bristol-Myers Squibb will close on acquisition of Celgene, to create leading biopharmaceutical company. With an extended portfolio of accomplished brands and new product launches, long-term company is well positioned to achieve steady and sustainable growth. Headquarter in Osaka, Japanese multinational Takeda is largest pharmaceutical company in Asia.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Samsung Biologics

Seoul-samsung BioLogics announced Tuesday that it will invest 1. 74 trillion won to build fourth pharmaceutical plant in Incheon as companies expect demand for contract drug manufacturing to surge in coming years. South Korean biomedicine manufacturer aims to increase its production capacity by 70 % by the end of 2022 and says it will hire around 1, 800 people for expansion. Contract manufacturing for pharmaceutical products is yet to meet demand, tae Han Kim, CEO of Samsung BioLogics, said at an online press conference Tuesday. There is a growing trend to outsource pharmaceutical manufacturing process, and we expect the market will grow on average 16 % per year. With new orders pouring in, Kim say, Samsung BioLogics will overwhelm its peers in terms of production scale and foster biotech as South Korea's growth sector. Due to huge costs involved in creating new biomedicines, pharmaceutical companies now tend to specialize in developing products and outsource manufacturing. Samsung Biologics rival Fujifilm Holdings of Japan recently decided to ramp up its production capacity with investment of over 100 billion yen. Samsung BioLogics already mass-produce drugs at three plants in the Incheon Free Economic Zone. In the first half of 2020 alone, companies have signed contracts for orders worth nearly 2. 5 times last year's total revenue, as the coronavirus pandemic has spurred demand. Plans to build fourth plant at Incheon come as the third facility is expected to reach full capacity in 2022. The new plant will add 256, 000 liters of capacity, for total capacity at four facilities of 620, 000 liters. This would put Samsung BioLogics ahead of rivals such as Switzerland's Lonza Group and Germany's Boehringer Ingelheim. Samsung Biologics share price closed over 4 % higher on Tuesday.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Daewoong Pharma

South Korea's Daewoong Pharmaceutical Co Ltd said on Tuesday it received Indian regulatory approval to test its anti-parasitic niclosamide drug to treat COVID-19 patients in early-stage human trial. The Phase 1 trial, approved by India's Central Drugs Standard Control Organization, will involve around 30 healthy participants to test safety and kickstart this month, Daewoong said in a statement. South Korean drugmaker is testing a drug in partnership with New Delhi-base Mankind Pharma Ltd, which will continue second and third phases of trials in India on mild and severe coronavirus patients. Drugmakers worldwide are scrambling to develop treatments for illness caused by novel coronavirus, which has killed nearly 739, 000 people globally since it first emerged late last year in China. Trial results from India will be used for export permits in Europe and the United States, said Daewoong. The company is also waiting for separate phase 1 trial approval from South Korea, Nathan Kim, vice-president at Daewoong's communications Office, told Reuters. Daewoong had said its anti-viral drug had completely eliminated novel coronavirus from animals lungs during pre-clinical testing.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Ildong Pharmaceutical

Ildong Pharmaceutical is an established and respected name in South Korea Pharmaceutical industry. They specialize in developing, manufacturing, and supplying pharmaceutical products. Ildong Pharmaceuticals researchers and scientists use state-of-art laboratories and equipment to develop new drugs to battle against resistant bacteria, malignant tumours, Alzheimers disease, obesity, and ageing. They are well known for their capacity in development of raw vitamins, probiotics, and antimicrobials. Ildong Pharmaceutical has developed a number of power brands such as Biovita, first commercial lactobacillus product to be introduced in South Korea, and Aronamin, lineup of popular multivitamins. The company also works with global pharmaceutical companies to manufacture original prescription drugs and utilize its internal synthesis capacity to manufacture a wide variety of generic prescription drugs. Ildong Pharmaceutical is currently expanding into functional health food, medical device, cosmetic, and beverage industries and evolving into a total healthcare company of global proportions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

GC Pharma

Yongin, South Korea, May 20, 2018 / PRNewswire /-GC Pharma, South Korean biopharmaceutical Company, today announced establishment of Curevo Inc. The newly established Seattle-base Company's goal is to support GC Pharma's vaccine development activities. Gc Pharma builds strategic collaboration and partnership with global health organizations IDRI and MIBR to form a new company. Curevo represents an important next step in GC Pharma's vaccine business. The new company will bring together GC Pharma's commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR's world class scientific expertise in vaccine, adjuvant and formulation development. Initial work will centre on advancing an innovative vaccine candidate against shingles to the clinical stage. Establishing Curevo signals crucial step forward in GC Pharma's long-standing dedication to preventing potentially serious diseases, say EC Huh, Ph. D. President of GC Pharma. This exciting collaboration will increase possibilities for immune-compromised populations to have better options. The bottom line is that this new collaboration will take advantage of the combined strength of these three organizations to more rapidly develop infectious disease vaccines and bring them to market, say Steve Reed, Ph. D., Idri's President, CEO and Founder. Mibr scientists have been focusing on discovering novel cancer therapeutics and vaccines. Curevo create excellent conduit to achieve those goals by joining forces with GC Pharma and IDRI, say Senyon Teddy Choe, Ph. D., Mibr's President and Director. Corey Casper, M. D., M. P. H. Idri's Chief Medical Officer, will lead shingles project of the new Company. Dr. Casper has more than 20 years of experience in designing, growing and sustaining internationally recognized programs in infection-related cancer, HIV, infection control and global oncology. He also has extensive experience leading multi-phased international clinical trials. Gc Pharma is biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquarter in South Korea, GC Pharma is largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's register, legal name. For more information, please visit www. Globalgreencross. Com a non-profit global health organization, IDRI takes a comprehensive approach to combating infectious diseases, combining high-quality science of research organization with product development capabilities of biotech companies to create new diagnostics, drugs and vaccines. Found in 1993, IDRI has 125 employees headquarter in Seattle with nearly 100 partners / collaborators around world. For more information, visit www. Idri. Org. As non-profit global research organization, MIBR is engaged in basic drug discovery research to combat infectious diseases, cancer, and rare diseases. Founded in 1984, MIBR is headquarter in southern Seoul with a number of research collaborations ongoing with GC Pharma. For more information, visit www. Mogam. Re. Kr. This release includes forward-looking statements, which express current beliefs and expectations of GC Pharma's management.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

LG Chem

Pdc * line Pharma grants exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for development and commercialization of PDC * lung cancer vaccine for lung cancer liege, Belgium, Grenoble, France and Seoul, South Korea, March 20, 2019-PDC * line Pharma, biotech Company developing new class of potent and scalable antigen presenting Cell, base on proprietary Cell line of Plasmacytoid Dendritic cells, announces today that IT has sign exclusive licensing and option agreement with LG Chem Life Sciences Company, Life Sciences division of LG Chem Ltd. This agreement, which includes development and commercialization collaboration agreement, opens new markets to PDC * line Pharma and expands the global footprint of its PDC * line-base cancer vaccine. Under terms of agreements, PDC * line Pharma will co-operate with LG Chem, who will have full rights in South Korea and exclusive option for other Asian countries, to develop and commercialize companys drug candidate, PDC * lung, in lung cancer. Pdc * lung is constitute of PDC * line load with HLA-A2 restrict peptides derive from six share tumor antigens. Pdc * line Pharma is eligible for upfront and near-term milestone payments, plus longer-term clinical development and regulatory milestones totaling up to €108M. The Company will also receive royalties based on net sales of licensed products in LG Chems Asian markets. Under terms of the agreement, PDC * line Pharma will continue developing its PDC * lung candidate in EU, US and global markets outside of Asia, and LG Chem will be responsible for future development and commercialization in its territories. Eric Halioua, president & CEO of PDC * line Pharma, say: We are very pleased to co-operate with LG Chem and to start development of our PDC * lung cancer vaccine in Asia. This licensing agreement is great opportunity for PDC * line Pharma to expand the scope of its immuno-oncology clinical programs and bring our technology to numerous patients around the world. Furthermore, agreement with LG-Chem Life Sciences Company, leading pharmaceutical Company in Korea, is a major endorsement for our unique PDC * line approach and its potential. Dr. Jeewoong Son, president of LG-Chem Life Sciences Company, say: We are delighted to start this strategic collaboration with PDC * line Pharma, great partnership to further expand LG Chems Cell-base cancer immunotherapy portfolio. Pdc * line Pharmas technology is back by cutting-edge Science and we believe we can extend its reach by bringing this novel therapy to a greater number of cancer patients. About PDC * line Pharma founded in 2014 as a spin-off of French Blood Bank, PDC * line Pharma is a Belgian-French biotech company that develops an innovative class of active immunotherapies for cancers, based on GMP-grade allogeneic therapeutic Cell line of Plasmacytoid Dendritic cells. Pdc * line is much more potent than conventional Dendritic Cell-base vaccines to prime and boost antitumor antigen-specific cytotoxic T-cells, including T cells specific for neoantigens, and is synergistic with checkpoint inhibitors. Technology can be applied to any type of cancer.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Celltrion

Celltrion is a South Korean pharmaceutical venture that develops biosimilars-generic equivalents of biopharmaceuticals-using microorganisms and animal cells. Remsima, biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America. Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. Company's plants in South Korea can produce 200, 000 liters of protein drugs per year. In addition to well-know treatments Remsima and breast cancer drug Herzuma, company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, US and Europe, where demand for biosimilars is growing rapidly. Because Celltrion is a research and development-orient company, its operating profit margin has remain high. It is one of the top companies on Kosdaq market for startups in terms of market capitalization.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Yuhan

Yuhan Pharmaceuticals is South Korean pharmaceutical and chemical company established in 1926 and headquarter in Daebang-dong, Dongjak-gu, Seoul, Korea. Yuhan recently established wholly owned subsidiary, named Yuhan USA, in San Diego. The Companies engage in research and development, and production of active pharmaceutical products and intermediates, such as antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds. It also offers Revanex, acid pump antagonist for treatment of peptic ulcers and gastritis-related mucosal injury. In addition, Company provides ETC products in various areas, and OTC products, such as vitamins and minerals, dermatology and analgesics drugs, and others. Additionally, company provides contract manufacturing services.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.